Behavioral therapies for drug abuse

American Journal of Psychiatry

Volumn 162, Issue 8, 2005, Pages 1452-1460

  Carroll, Kathleen M ^a   Onken, Lisa S ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; METHADONE; NICOTINE; OPIATE;

ABSTINENCE; ALCOHOL ABUSE; BEHAVIOR THERAPY; CANNABIS ADDICTION; CIGARETTE SMOKING; COGNITIVE THERAPY; DETOXIFICATION; DRUG ABUSE; DRUG DEPENDENCE; FAMILY COUNSELING; FAMILY THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERVIEW; INTRAVENOUS DRUG ABUSE; MARITAL THERAPY; METHADONE TREATMENT; MODEL; MOTIVATION; OPIATE ADDICTION; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK REDUCTION; SMOKING CESSATION;

ADOLESCENT; ADULT; BEHAVIOR THERAPY; CLINICAL TRIALS; COGNITIVE THERAPY; COUNSELING; FAMILY THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK-TAKING; SUBSTANCE-RELATED DISORDERS;

EID: 23344446433     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.8.1452     Document Type: Review

References (105)

1. Sargent S: The treatment of depressive states. Int J Neurol 1967; 6:53-64
2. Agras WS, Chapin HN, Oliveau DC: The natural history of phobia. Arch Gen Psychiatry 1972; 26:315-317
3. Marks IM: New approaches to the treatment of obsessive-compulsive disorders. J Nerv Ment Dis 1973; 156:420-426
4. Waskow IE: Specification of the technique variable in the NIMH Treatment of Depression Collaborative Research Program, in Psychotherapy Research: Where Are We and Where Should We Go? Edited by Williams JBW, Spitzer RL. New York, Guilford, 1984, pp 150-159
5. Docherty JP: Implications of the technological model of psychotherapy. Ibid, pp 139-149
6. Elkin I, Pilkonis PA, Docherty JP, Sotsky SM: Conceptual and methodologic issues in comparative studies of psychotherapy and pharmacotherapy, I: active ingredients and mechanisms of change. Am J Psychiatry 1988; 145:909-917
7. Elkin I, Pilkonis PA, Docherty JP, Sotsky SM: Conceptual and methodological issues in comparative studies of psychotherapy and pharmacotherapy, II: nature and timing of treatment effects. Am J Psychiatry 1988; 145:1070-1076
8. Woody GE, Luborsky L, McLellan AT, O'Brien CP, Beck AT, Blaine JD, Herman L, Hole A: Psychotherapy for opiate addicts: does it help? Arch Gen Psychiatry 1983; 40:639-645
9. Onken LS, Blaine JD: Psychotherapy and counseling research in drug abuse treatment: questions, problems, and solutions. NIDA Research Monogr 1990; 104:1-8
10. Kang SY, Kleinman PH, Woody GE, Millman RB, Todd TC, Kemp J, Lipton DS: Outcomes for cocaine abusers after once-a-week psychosocial therapy. Am J Psychiatry 1991; 148:630-635
11. Kleber HD, Gawin FH: Cocaine abuse: a review of current and experimental treatments, in Cocaine: Pharmacology, Effects and Treatment of Abuse. DHHS Publication (ADM) 84-1326. Edited by Grabowski J. Rockville, Md, National Institute on Drug Abuse, 1984, pp 111-129
12. Onken LS, Blaine JD, Battjes R: Behavioral therapy research: a conceptualization of a process, in Innovative Approaches for Difficult-to-Treat Populations. Edited by Henggeler SW, Santos AB. Washington, DC, American Psychiatric Press, 1996, pp 477-485
13. Rounsaville BJ, Carroll KM, Onken LS: A stage model of behavioral therapies research: getting started and moving on from Stage I. Clin Psychol Sci Pract 2001; 8:133-142
14. Kazdin AE: Comparative outcome studies in psychotherapy: methodological issues and strategies. J Consult Clin Psychol 1986; 54:95-105
15. Carroll KM, Rounsaville BJ: Bridging the gap between research and practice in substance abuse treatment: a hybrid model linking efficacy and effectiveness research. Psychiatr Serv 2003; 54:333-339
16. Stitzer ML, Bickel WK, Bigelow GE, Liebson IA: Effect of methadone dose contingencies on urinalysis test results of polydrug abusing methadone maintenance patients. Drug Alcohol Depend 1986; 18:341-348
17. Stitzer ML, Iguchi MY, Felch LJ: Contingent take-home incentives: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 1992; 60:927-934
18. Dolan MP, Black JL, Penk WE, Rabinowitz R, DeFord HA: Contracting for treatment termination to reduce illicit drug use among methadone maintenance treatment failures. J Consult Clin Psychol 1985; 53:549-551
19. Kidorf M, Stitzer ML: Contingent use of take-homes and split-dosing to reduce illicit drug use of methadone patients. Behav Ther 1996; 27:41-51
20. Iguchi MY, Stitzer ML, Bigelow GE, Liebson IA: Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend 1988; 22:1-7
21. Stitzer ML, Iguchi MY, Kidorf M, Bigelow GE: Contingency management in methadone treatment: the case for positive incentives, in Behavioral Treatments for Drug Abuse and Dependence. Edited by Onken LS, Blaine JD, Boren JJ. Rockville, Md, National Institute on Drug Abuse, 1993, pp 19-36
22. Budney AJ, Higgins ST, Mercer DE, Carpenter G: A Community Reinforcement Plus Vouchers Approach: Treating Cocaine Addiction. NIH Publication 98-4309. Rockville, Md, National Institute on Drug Abuse, 1998
23. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL: Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 2000; 68:64-72
24. Higgins ST, Badger GJ, Budney AJ: Initial abstinence and success in achieving longer term cocaine abstinence. Exp Clin Psychopharmacol 2000; 8:377-386
25. Higgins ST, Sigmon SC, Wong CJ, Heil SH, Badger GJ, Donham R, Dantona RL, Anthony S: Community reinforcement therapy for cocaine-dependent outpatients. Arch Gen Psychiatry 2003; 60:1043-1052
26. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA: Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 1997; 65:803-810
27. Shoptaw S, Rotheram-Fuller E, Yang X, Frosch D, Nahom D, Jarvik ME, Rawson RA, Ling W: Smoking cessation in methadone maintenance. Addiction 2002; 97:1317-1328
28. Budney AJ, Higgins ST, Radonovich KJ, Novy PL: Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000; 68:1051-1061
29. Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR: Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54:127-135
30. Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan D, Frankfurter TL, Triffleman EG, Shi J, Rounsaville BJ: Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58:755-761
31. Carroll KM, Sinha R, Nich C, Babuscio T, Rounsaville BJ: Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002; 10:54-63
32. Iguchi MY, Belding MA, Morral AR, Lamb RJ, Husband SD: Reinforcing operants other than abstinence in drug abuse treatment: an effective alternative for reducing drug use. J Consult Clin Psychol 1997; 65:421-428
33. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL: Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53:409-415
34. Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL: Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66:811-824
35. Silverman K, Wong CJ, Higgins ST, Brooner RK, Montoya ID, Contoreggi C, Umbricht-Schneiter A, Schuster CR, Preston KL: Increasing creasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend 1996; 41:157-165
36. Silverman K, Svikis DS, Robles E, Stitzer ML, Bigelow GE: A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol 2001; 9:14-23
37. Silverman K, Svikis DS, Wong CJ, Hampton J, Stitzer ML, Bigelow GE: A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol 2002; 10:228-240
38. Retry NM, Martin B, Cooney JL, Kranzler HR: Give them prizes and they will come: contingency management treatment of alcohol dependence. J Consult Clin Psychol 2000; 68:250-257
39. Retry NM, Martin B: Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J Consult Clin Psychol 2002; 70:398-405
40. Retry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ: Prize reinforcement contingency management for treating cocaine abusers: how low can we go, and with whom? Addiction 2004; 99:349-360
41. Crowley TJ: Research on contingency management treatment of drug dependence: clinical implications and future directions, in Motivating Behavior Change Among Illicit Drug Abusers. Edited by Higgins ST, Silverman K. Washington, DC, American Psychological Association, 1999, pp 345-370
42. Carroll KM: A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIH Publication 98-4308. Rockville, Md, National Institute on Drug Abuse, 1998
43. Marlatt GA, Gordon JR: Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York, Guilford, 1985
44. Miller WR, Wilbourne PL: Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002; 97:265-277
45. Miller WR, Brown JM, Simpson TL, Handmaker NS, Bien TH, Luckie LF, Montgomery HA, Hester RK, Tonigan JS: What works? a methodological analysis of the alcohol treatment literature, in Handbook of Alcoholism Treatment Approaches: Effective Alternatives. Edited by Hester RK, Miller WR. Boston, Allyn & Bacon, 1995, pp 12-44
46. DeRubeis RJ, Crits-Christoph P: Empirically supported individual and group psychological treatments for adult mental disorders. J Consult Clin Psychol 1998; 66:37-52
47. Irvin JE, Bowers CA, Dunn ME, Wong MC: Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol 1999; 67:563-570
48. Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM: Superior efficacy of cognitive-behavioral therapy for crack cocaine abusers: main and matching effects. J Consult Clin Psychol 1998; 66:832-837
49. Rohsenow DJ, Monti PM, Martin RA, Michalec E, Abrams DB: Brief coping skills treatment for cocaine abuse: 12-month substance use outcomes. J Consult Clin Psychol 2000; 68:515-520
50. Monti PM, Rohsenow DJ, Michalec E, Martin RA, Abrams DB: Brief coping skills treatment for cocaine abuse: substance abuse outcomes at three months. Addiction 1997; 92:1717-1728
51. McKay JR, Alterman AI, Cacciola JS, Rutherford MJ, O'Brien CP, Koppen haver J: Group counseling versus individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence. J Consult Clin Psychol 1997; 65:778-788
52. Carroll KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow PM, Bisighini RM, Gawin FH: Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51:177-197
53. Carroll KM, Rounsaville BJ, Gawin FH: A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991; 17:229-247
54. Rosenblum A, Magura S, Palij M, Foote J, Handlesman L, Stimmel B: Enhanced treatment outcomes for cocaine-using methadone patients. Drug Alcohol Depend 1999; 54:207-218
55. Carroll KM, Mich C, Ball SA, McCance-Katz E, Rounsaville BJ: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998; 93:713-728
56. Carroll KM, Fenton LR, Ball SA, Nich C, Frankfurter TL, Shi J, Rounsaville BJ: Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo controlled trial. Arch Gen Psychiatry 2004; 64:264-272
57. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin FH: One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51:989-997
58. Carroll KM, Nich C, Ball SA, McCance-Katz EF, Frankfurter TF, Rounsaville BJ: One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol abusers: sustained effects of treatment. Addiction 2000; 95:1335-1349
59. Barlow DH: Cognitive behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997; 58(suppl 2):32-36
60. Hollon SD, Shelton RC, Davis DD: Cognitive therapy for depression: conceptual issues and clinical efficacy. J Consult Clin Psychol 1993; 61:270-275
61. Rawson RA, Huber A, McCann MJ, Shoptaw S, Farabee D, Reiber C, Ling W: A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance for cocaine dependence. Arch Gen Psychiatry 2002; 59:817-824
62. Epstein DE, Hawkins WE, Covi L, Umbricht A, Preston KL: Cognitive behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav 2003; 17:73-82
63. Otto MW, Pollack MH, Sachs GS, Reiter SR, Maltzer-Brody S, Rosenbaum JF: Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150:1485-1490
64. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A: Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994; 151:876-881
65. Rawson RA, Marinelli Casey PJ, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J (Methamphetamine Treatment Project Corporate Authors): A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004; 99:703-717
66. Miller WR, Rollnick S: Motivational Interviewing: Preparing People for Change, 2nd ed. New York, Guilford, 2002
67. MTP Research Group: Brief treatments for cannaibis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004; 72:455-466
68. Dunn C, Deroo I, Rivara FP: The use of brief interventions adapted from motivational interviewing a cross behavioral domains: a systematic review. Addiction 2001; 96:1725-1742
69. Burke BL, Arkowitz H, Menchola M: The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol 2003; 71:843-861
70. Project MATCH Research Group: Matching alcohol treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997; 58:7-29
71. Stephens R, Roffman RA, Curtin L: Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000; 68:898-908
72. Carey MP, Maisto SA, Kalichman SC, Forsythe AD, Wright EM, Johnson BT: Enhancing motivation to reduce the risk of HIV infection for economically disadvantaged urban women. J Consult Clin Psychol 1997; 65:531-541
73. Carey MP, Braaten LS, Maisto SA, Gleason JR, Forsythe AD, Durant LE, Jaworski BC: Using information, motivational enhancement, and skills training to reduce the risk of HIV infection for low-income urban women: a second randomized clinical trial. Health Psychol 2000; 19:3-11
74. Miller WR, Yahne CE, Tonigan JS: Motivational interviewing in drug abuse services: a randomized trial. J Consult Clin Psychol 2003; 71:754-763
75. Donovan DM, Rosengren DB, Downey L, Cox GC, Sloan KL: Attrition prevention with individuals awaiting publicly funded drug treatment. Addiction 2001; 96:1149-1160
76. Booth RE, Kwiatkowski C, Iguchi MY, Pinto F, John D: Facilitating treatment entry among out-of-treatment injection drug users. Public Health Rep 1998; 113(suppl 1):116-128
77. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garret R, Sly K, Devir H, Terry M: Motivational interviewing among psychiatric inpatients with substance use disorders. Acta Psychiatr Scand 2002; 106:233-240
78. Henggeler SW, Pickrel SG, Brondino MJ, Crouch JL: Eliminating (almost) treatment dropout of substance abusing or dependent delinquents through home-based multisystemic therapy. Am J Psychiatry 1996; 153:427-428
79. Liddle HA, Dakof GA, Parker K, Diamond GS, Barrett K, Tejeda M: Multidimensional family therapy for adolescent drug abuse: results of a randomized clinical trial. Am J Drug Alcohol Abuse 2001; 27:651-688
80. Stanton MD, Shadish WR: Outcome, attrition, and family-couples treatment for drug abuse: a meta-analysis and review of the controlled, comparative studies. Psychol Bull 1997; 122:170-191
81. Liddle HA, Dakof G: Efficacy of family therapy for drug abuse: promising but not definitive. J Marital Fam Ther 1995; 21:511-543
82. Waldron HB: Adolescent substance abuse and family therapy outcome: a review of randomized trials. Adv Clin Child Psychol 1997; 19:199-234
83. Deas D, Thomas SE: An overview of controlled studies of adolescent substance abuse treatment. Am J Addict 2001; 10:178-189
84. Waldron HB, Slesnick N, Brody JL, Turner CW, Peterson TR: Treatment outcomes for adolescent substance abuse at 4- and 7-month assessments. J Consult Clin Psychol 2001; 69:802-813
85. Fals-Stewart W, O'Farrell TJ, Birchler GR: Behavioral couples therapy for male substance-abusing patients: a cost outcomes analysis. J Consult Clin Psychol 1997; 65:789-802
86. Fals-Stewart W, O'Farrell TJ, Birchler GR: Behavioral couples therapy for male methadone patients: effects on drug-using behavior and relationship adjustment. Behav Ther 2001; 32:391-411
87. Fals-Stewart W, O'Farrell TJ: Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol 2003; 71:432-442
88. Kelley ML, Fals-Stewart W: Couples- versus individual-based therapy for alcohol and drug abuse: effects on children's psychosocial functioning. J Consult Clin Psychol 2002; 70:417-427
89. Azrin NH, Donohue B, Besalel VA, Kogan ES, Acierno R: Youth drug abuse treatment: a controlled outcome study. J Child Adolesc Subst Abuse 1994; 3:1-16
90. Henggeler SW, Borduin CM: Family Therapy and Beyond: A Multisystemic Approach to Treating the Behavior Problems of Children and Adolescents. Pacific Grove, Calif, Brooks/Cole, 1990
91. Henggeler SW, Melton GB, Smith LA: Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol 1992; 60:953-961
92. Borduin CM, Mann BJ, Cone LT, Henggeler SW, Fucci BR, Blaske DM, Williams RA: Multisystemic treatment of serious juvenile offenders: long-term prevention of criminality and violence. J Consult Clin Psychol 1995; 63:569-578
93. Huey SJ, Henggeler SW, Brondino MJ, Pickrel SG: Mechanisms of change in multisystemic therapy: reducing delinquent behavior through therapist adherence and improved family and peer functioning. J Consult Clin Psychol 2000; 68:451-467
94. Henggeler SW, Clingempeel WG, Brondino MJ, Pickrel SG: Four-year follow-up of multisystemic therapy with substance-abusing and substance-dependent juvenile offenders. J Am Acad Child Adolesc Psychiatry 2002; 41:868-874
95. Szapocznik J, Hervis O, Schwartz S: Brief Strategic Family Therapy for Adolescent Drug Abuse. NIH Publication 03-4751. Bethesda, Md, National Institute on Drug Abuse, 2003
96. Szapocznik J, Perez-Vidal A, Brickman AL, Foote FH, Santisteban DA, Hervis O, Kurtines WM: Engaging adolescent drug abusers and their families in treatment: a strategic structural systems approach. J Consult Clin Psychol 1988; 56:552-557
97. Santisteban DA, Coatsworth JD, Perez-Vidal A, Mitrani V, Jean-Gilles M, Szapocznik J: Engaging behavior problem/drug abusing youth and their families in treatment: a replication and further exploration of the factors that contribute to differential effectiveness. J Fam Psychol 1996; 10:35-44
98. Coatsworth JD, Santisteban DA, McBride CK, Szapocznik J: Brief strategic family therapy versus community control: engagement, retention, and an exploration of the moderating role of adolescent severity. Fam Process 2001; 40:313-332
99. Szapocznik J, Kurtines WM, Foote FH, Perez-Vidal A, Hervis O: Conjoint versus one-person family therapy: some evidence for the effectiveness of conducting family therapy through one person. J Consult Clin Psychol 1986; 54:395-397
100. Crits-Christoph P, Siqueland L, Blaine JD, Frank A, Luborsky L, Onken LS, Muenz L, Thase ME, Weiss RD, Gastfriend DR, Woody G, Barber JP, Butler S, Dale D, Salloum I, Bishop S, Najavits L, Lis J: Psychosocial treatments for cocaine dependence: results of the National Institute on Drug Abuse Collaborative Cocaine Study. Arch Gen Psychiatry 1999; 56:495-502
101. Mercer DE, Woody GE: An Individual Drug Counseling Approach to Treat Cocaine Addiction: The Collaborative Cocaine Treatment Study Model. NIH Publication 99-4380. Rockville, Md, National Institute on Drug Abuse, 1999
102. Woody GE, Gallop R, Luborsky L, Blaine JD, Frank A, Salloum IM, Gastfriend DR, Crits-Christoph P (Cocaine Psychotherapy Study Group): HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study. J Acquir Immune Defic Syndr 2003; 33:82-87
103. Sorensen JL, Copeland AL: Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59:17-31
104. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J: A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol 2003; 22:223-228
105. Avants SK, Margolin A, Usubiaga MH, Doebrick C: Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of harm reduction group therapy. J Subst Abuse Treat 2004; 26:67-78